Account
Webinar
31.10.2023
NICE’s Proportionate Approach to Technology ...

Webinar: Our experts discuss NICE's proportionate approach to technology appraisals and the implicat...

Read more
Publications
25.10.2023
ISPOR Europe 2023: Can Just Three PICOs be Feasibl...

This research aims to understand if just three PICOs are feasible by analysing recent HTA assessment...

Read more
Publications
25.10.2023
ISPOR Europe 2023: How Aware Are Biotech and Pharm...

Our research aims to gauge awareness of the new EU HTA process within the pharmaceutical industry in...

Read more
Publications
25.10.2023
ISPOR Europe 2023: How Has NICE’s Severity M...

Our study aims to understand how the severity modifier has been implemented so far and its impact on...

Read more
Articles
11.10.2023
Unlocking the Potential of Cell and Gene Therapy: ...

We outline the challenges pharma companies encounter when launching cell and gene therapies, and ass...

Read more
Insider Insights
06.10.2023
Germany’s Health Ministry Shifts Focus to Di...

Germany is reshaping its Ministry of Health to prioritize the prevention of diseases like cancer, de...

Read more
Webinar
06.10.2023
Orphan Medicine Market Access in Europe

Webinar: Our experts discuss Orphan medicine market access in Europe including the impact of EU HTA ...

Read more
Articles
07.09.2023
Prescription price puzzles: the sky-high cost of O...

This article explores the significant disparities between the US and Europe regarding orphan drugs a...

Read more
Insider Insights
17.08.2023
Managed entry agreements: €195m saved by the Ita...

MEAs resulted in 195.2 million of savings for the Italian healthcare system, according to AIFA’s M...

Read more
Articles
21.06.2023
What are the current unmet needs in Oncology?

We explore the innovative assessment criteria for novel cancer therapies and the unmet needs in onco...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.